Other Hallucinogen Use Disorder

Clinical picture

• Use is typically episodic and social rather than daily, and tolerance to perceptual effects builds within days but resolves after a short break.
• Acute intoxication brings visual illusions, synesthesia, depersonalization, altered time sense, and labile affect with orientation preserved.
• Bad trips present as panic, paranoia, and derealization lasting hours, with mydriasis, tachycardia, hypertension, and hyperthermia on exam.
• No clinically meaningful withdrawal syndrome occurs, so criteria are met through impaired control, risky use, and social or role consequences.
• Hallucinogen persisting perception disorder brings trails, halos, afterimages, and visual snow that are ego-dystonic and fully reality-tested.
• MDMA users present with bruxism, trismus, hyponatremia from excessive water intake, and a midweek dysphoric crash after weekend dosing.

Criteria snapshot

• Requires at least 2 of 11 problematic use indicators within 12 months, the same criterion set applied across the substance use disorders.
• Withdrawal is explicitly excluded from the hallucinogen criterion set, because no reliable withdrawal syndrome has been established.
• Severity is graded by symptom count: mild 2-3, moderate 4-5, and severe 6 or more, with early and sustained remission specifiers available.
• Phencyclidine use disorder is coded separately from other hallucinogen use disorder despite substantial overlap in clinical presentation.
• Related diagnoses include hallucinogen intoxication, hallucinogen persisting perception disorder, and the hallucinogen-induced mental disorders.

Neurobiology

• Classic psychedelics are 5-HT2A receptor agonists acting on layer V cortical pyramidal neurons, disrupting thalamocortical sensory filtering.
• MDMA acts primarily as a serotonin releaser through transporter reversal, with oxytocin release producing the prosocial entactogenic effect.
• Rapid tachyphylaxis follows 5-HT2A receptor downregulation, so daily dosing loses effect within roughly 3 days and cross-tolerance is common.
• Physiologic dependence is minimal, since classic hallucinogens do not directly drive mesolimbic dopamine release the way stimulants and opioids do.
• HPPD is hypothesized to reflect disinhibition of visual processing after loss of GABAergic interneuron control in occipital and visual association cortex.
• Heavy MDMA exposure is linked to reduced SERT binding and verbal memory deficits, plus serotonin syndrome risk when combined with serotonergic drugs.

Psychology

• Set and setting powerfully shape the experience; expectancy, mood, and environment predict euphoria versus panic more reliably than dose alone.
• Use is often driven by curiosity, spiritual seeking, and peer context rather than by craving, which limits classic compulsive addiction patterns.
• Repeated bad trips condition anticipatory anxiety, and HPPD distress is amplified by health anxiety and hypervigilant monitoring of the visual field.
• Ego dissolution can destabilize patients with fragile identity, precipitating prolonged derealization or a first frank psychotic episode.
• Reassurance and normalization reduce HPPD impairment, since catastrophic interpretation of benign visual noise is what sustains the distress.

Differential & comorbidity

• Differentiate from primary psychosis by preserved insight, visual rather than auditory dominance, and a clear temporal link to ingestion.
• Exclude PCP intoxication with nystagmus, violence, and analgesia, anticholinergic delirium, and stimulant or cannabis-induced psychosis.
• Comorbid cannabis, alcohol, stimulant, and tobacco use disorders are common, and polysubstance use frequently muddies the presentation.
• HPPD affects only a small minority of users and must be separated from migraine aura, visual snow syndrome, and occipital lobe seizures.
• Screen for schizophrenia spectrum vulnerability, since hallucinogen use can precipitate earlier onset in genetically at-risk individuals.

Pharmacologic treatment

• No pharmacotherapy is approved for the use disorder itself; management is supportive and directed at comorbidity and at acute episodes.
• Bad trips respond to a quiet low-stimulus room, calm reassurance, and lorazepam 1-2 mg as needed for severe agitation or panic.
• Avoid antipsychotics where possible in classic hallucinogen intoxication, since they may prolong dysphoria; reserve them for true psychosis.
• HPPD case reports support lamotrigine and clonazepam 1-2 mg/day, along with avoiding cannabis and stimulants, which reliably worsen symptoms.
• MDMA toxicity requires aggressive cooling, benzodiazepines for agitation, and close sodium monitoring for life-threatening hyponatremia.

Psychotherapy

• Motivational interviewing addresses ambivalence directly, since many users regard the substance as beneficial rather than as harmful.
• CBT with relapse prevention targets contexts, festival and rave settings, and polysubstance patterns rather than physiologic craving.
• Contingency management improves abstinence in polysubstance-using young adults, particularly where stimulants are also involved.
• Psychoeducation and reassurance are the first-line intervention for HPPD, often reducing distress without any medication at all.
• Family and peer network interventions help adolescents, whose use is shaped far more by social group norms than by pharmacology.

Adjunct options

• Harm reduction includes drug checking for fentanyl and NBOMe adulterants, hydration guidance, and never using alone or in unsafe settings.
• Warn explicitly about serotonin syndrome when MDMA is combined with SSRIs, MAOIs, linezolid, or tramadol.
• Distinguish supervised psilocybin and MDMA research protocols from recreational use; trial safety data do not generalize to street supply.
• Screen for hyponatremia, hyperthermia, rhabdomyolysis, and hepatic injury after any MDMA-related emergency department presentation.
• Use ASAM criteria to set level of care, though most patients are managed outpatient given the absence of physiologic withdrawal.

Clinical pearls

• No withdrawal syndrome; that criterion is excluded for hallucinogen use disorder.
• HPPD flashbacks are ego-dystonic with intact reality testing, unlike psychosis.
• Tolerance to LSD builds in ~3 days and reverses after a few days off.